Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gantenerumab in Early Alzheimer's Disease (GRADUATE II)
NCT03443973Phase 3Terminated
- Sponsor
- Roche
- Start
- Aug 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Started Aug 2018; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03443973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443973.